GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (NAS:ANEB) » Definitions » Price-to-Operating-Cash-Flow

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of May. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-05-04), Anebulo Pharmaceuticals's share price is $2.95. Anebulo Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.37. Hence, Anebulo Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Anebulo Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

ANEB's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 26.265
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Anebulo Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.07. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.37.


Anebulo Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Anebulo Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23
Price-to-Operating-Cash-Flow
- - - -

Anebulo Pharmaceuticals Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anebulo Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Anebulo Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anebulo Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.



Anebulo Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Anebulo Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=2.95/-0.372
=

Anebulo Pharmaceuticals's Share Price of today is $2.95.
Anebulo Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.37.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Anebulo Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Executives
Bimal R. Shah director C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052
Richard Anthony Cunningham, director, officer: Chief Executive Officer ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Dan George officer: Chief Financial Officer 1412 62ND STREET, EMERYVILLE CA 94608
Sandra A. Gardiner officer: Acting Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kenneth C Cundy officer: Chief Scientific Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Simon Allen director, officer: Chief Executive Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Aron R. English director, 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Kenneth Lin director PO BOX 1005, LOS ALTOS CA 94022
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949
22nw Fund, Lp 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Joseph F. Lawler director, 10 percent owner 2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734
Areta Kupchyk director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
22nw, Lp 10 percent owner, other: See Explanation of Response 590 1ST AVE S, UNIT C1, SEATTLE WA 98104

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Headlines

From GuruFocus